6 Years Study on Changes in Bone Quality, Bone Turnover and Curve Severity in AIS With and Without Calcium and Vit-D Supplementation
NCT ID: NCT02904421
Last Updated: 2019-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
330 participants
OBSERVATIONAL
2016-10-31
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To investigate and compare the changes in bone mineral density (BMD), trabecular bone micro-architecture, bone strength, and curve severity at a mean of 6 years longitudinal follow up in AIS girls with low bone mass between Group A and B:
1. Group A: subjects followed at a mean of 4 years after completion of 2-year calcium and Vit-D supplementation and
2. Group B: subjects without calcium and Vit-D supplementation
2. To evaluate the correlation between changes in BMD, trabecular bone micro-architecture, and bone strength documented in Objective 1 with changes in serum bone turnover markers
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One important health threat that deserves special attention is osteopenia as defined by Bowden et al. for children having BMD age and gender-adjusted Z-score \< -1. 30-38% of AIS girls were osteopenic. Osteopenia could persist across puberty and was found to be a significant and independent prognostic factor for curve progression in AIS. Osteopenia was also found to be associated with low dietary calcium (Ca) intake at a median of 400mg/day among AIS girls. The low Ca intake was significantly correlated with age-adjusted peripheral volumetric bone mineral density (vBMD) measured by peripheral quantitative computed tomography (pQCT), as well as axial and peripheral areal BMD (aBMD) measured by Dual-Energy X-ray Absorptiometry (DXA).
Low calcium intake when coupled with low Vit-D status can seriously affect a child's bone health. Without Vit-D, only 10 to 15% of dietary calcium is absorbed, and 1,25-(OH)2Vit-D can increase intestinal calcium absorption to 30-40%. Vit-D insufficiency or disturbance in Vit-D physiology is associated with osteopenia, deranged muscle function and ligamentous laxity which could potentially predispose AIS subjects to curve progression.
Given that serum 25(OH)Vit-D level was also found to be low at a mean level of 41.6 nmol/L among AIS subjects, our group has conducted the first 2-year randomized double-blinded placebo-controlled trial using calcium and Vit-D supplementation for young AIS girls with low bone mass (the Cal study). There were three study groups in the trial, namely Group 1 (the placebo group), Group 2 (the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day) and Group 3 (the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day). The study showed strong evidences of positive bone accretion effects and therapeutic control of curve progression in groups with supplementation (Group 2 and 3). Following the therapeutic gain in BMD and improvement in bone quality with 2-year intervention with calcium and Vit-D supplementation, it will be important to evaluate if the effects persist after supplement withdrawal. This study would help to address this key issue by evaluating whether the beneficial effects of 2-year calcium and Vit-D supplementation persist at an average of 4 years after withdrawal of supplementation. The BMD, trabecular bone micro-architecture, bone strength, image-based and serum bone turnover parameters, and curve severity at 4 years after withdrawal of supplement would be compared with measurements done before and at end of supplementation.
Outcome of this study will provide important scientific data on the long term effects of 2-year calcium and Vit-D supplementation, thus justifying the need of lifestyle modification, duration and dose of supplementation for better bone health and curve control in adolescents suffering from AIS. If the beneficial effects are proven to be sustainable, the 2-year calcium and Vit-D supplements can be incorporated into the treatment protocol for AIS not only in Hong Kong, but also in Mainland China and other parts of the world; otherwise longer period of supplementation for sustained positive bone accretion effects and prevention of curve progression will be desirable for attaining peak bone mass and curve control to prevent osteopenia-related and scoliosis-related complications when approaching adulthood.
This six years longitudinal follow-up study with 2-year active supplementation period and 4-year post-withdrawal follow up for this cohort of adolescent girls is unique. Not only are the effects of calcium and vitamin D supplementation being followed, the placebo group in the original clinical trial provides the longitudinal changes on anthropometric, bone density, bone quality parameters and curve severity which will yield important reference information for local adolescents with AIS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
the placebo group
No interventions assigned to this group
Group 2
the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
No interventions assigned to this group
Group 3
the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with fracture
16 Years
21 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tsz-ping Lam
Clinical Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tsz Ping Lam
Role: PRINCIPAL_INVESTIGATOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Orthopaedics and Traumatology, Prince of Wales Hospital
Hong Kong, Hong Kong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CALTC4_v1
Identifier Type: -
Identifier Source: org_study_id